Fulcrum Therapeutics, Inc. Common Stock
FULCFulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that address genetically defined diseases. The company leverages its gene control platform to identify and develop treatments aimed at restoring or modulating gene expression to improve patient outcomes.
Company News
The U.S. firmware signing platform market is projected to grow from $0.40B in 2025 to $1.39B by 2033, driven by increasing demand for secure device updates across IoT, automotive, medical, and industrial systems, with a 16.78% CAGR.
Fulcrum Therapeutics has priced a public offering of 11,851,853 common stock shares and pre-funded warrants, expecting to raise $175.0 million to fund research, development, and potential acquisitions.
Fulcrum Therapeutics reported positive Phase 1b trial results for pociredir, an oral medication for sickle cell disease, showing significant increases in fetal hemoglobin and promising safety profile at the 20 mg dose level.
Datanomix and Fulcrum announced a strategic partnership to integrate ERP and production monitoring technologies, enabling manufacturers to unify job planning, scheduling, and live production tracking with real-time insights.
Fulcrum Therapeutics granted 47,450 non-statutory stock options to new employees at $9.50 per share, with a ten-year term and four-year vesting schedule.
